Tempus is one of the hottest start-ups in the city of Chicago and it has been in that position for the better part of the past three years. Tempus was co-founded by Eric Lefkofsky, an entrepreneur who specializes in big data, back in 2015. The company’s core goal was to create a conduit for molecular data and cancer care research to be funneled into a single database. The goal of this project, according to Lefkofsky, was to use big data as a path to identifying trends in effective care within the population of patients suffering from cancer.
Eric Lefkofksky rose to fame with his work at Groupon but he has been single-minded in his pursuit of making Tempus a mainstay in the medical world. After having seen what it is like to be within the cancer treatment system, Lefkofsky knew that his work with Tempus was extremely important. Tempus’ own faith in the project notwithstanding, it appears that other big financial providers are looking to help prop the company up for the long run. Tempus recently surpassed the $1.1 billion evaluation mark which makes it one of the few Chicago based startups to reach the vaunted Unicorn status that is so hard to acquire.
Lefkofsky has focused on allowing Tempus to connect with not just doctors and drug companies, but hospitals as well. Lefkofsky points to their success reaching to these different parts of the market while citing it as a fundamental shift in paradigm of things. Lefkofsky says of Tempus’ traction that things have been ‘kind of amazing’ thus far.
At the time of this writing, Tempus has nearly 400 employees on their roster. However, due to Tempus’ success, the company is adding nearly 30 new employees every single month to keep up with the work that they are doing. RIght now Tempus is focused on collecting molecular data of patients that are undergoing treatment and this comes in many shapes and forms. Tempus works with digital information but it can also be used to scan and port in physical information, such as handwritten doctor’s notes. With any luck, the Tempus database can lead to very real change in the cancer care world.
To Learn More Click Here